Authority: Supreme Court of India, Civil Original Jurisdiction
Order Date: 16 November 2026
Case Overview
- Petitioners: Indies Pharma Jamaica Limited, a pharmaceutical company incorporated in Jamaica.
- Respondents: Zydus Lifesciences Limited (formerly Cadilla Healthcare Limited), incorporated in India.
- Dispute arises from a Contract Manufacturing Agreement dated 20 May 2021 and a Letter of Intent dated 14 December 2020 concerning technology transfer, contract manufacturing, and supply of a generic version of the drug Nelarabine for commercialization in the United States.
- Article 18(a) of the CMA mandates arbitration under the Arbitration and Conciliation Act, 1996, with seat in Ahmedabad, India.
- Alleged delays in completing scientific studies and deliverables required for filing an Abbreviated New Drug Application (ANDA) with USFDA led to a legal notice on 18 November 2024; respondent declined settlement on 9 December 2024.
- Petition filed under Section 11(6) and Section 11(12)(a) of the Act on 2 April 2025 seeking appointment of a sole arbitrator; respondent replied on 2 May 2025 disputing arbitrability and refusing consent.
Final Outcome
- The Court allowed the arbitration petition.
- Hon’ble Mr. Justice Rashmin M. Chhaya, former Chief Justice of Gauhati High Court, appointed as sole arbitrator to adjudicate the disputes.
- Seat and venue of arbitration confirmed as Ahmedabad, India, per Article 18(a) of the CMA.
- The arbitrator may fix his fees after consultation with the parties.
- The petition is allowed in the terms of the order; any pending interlocutory applications are disposed of.
Topics: Arbitration, Pharmaceutical Contract Dispute, Supreme Court Order